Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Boda

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Orvosi Hetilap|April 4, 1993
[Heparin-Ca is not identical with low molecular weight heparin (LMWH)]Z Boda
Orvosi Hetilap|February 12, 1998
[Fibrinogen as an independent cardiovascular risk factor and the question of treatment with fibrinogen-lowering drugs]Z Boda
Lancet (London, England)|July 5, 1980
Haemostatic balance in congenital deficiency of platelet cyclo-oxygenaseK Rak, Z Boda
Orvosi Hetilap|June 17, 1984
[Laboratory control of patients treated with Syncumar]Z Boda, K Rák
Orvosi Hetilap|August 25, 1996
[Fibrinolysis and vascular diseases]M Udvardy, Z Boda
Orvosi Hetilap|October 29, 1989
[Subcutaneous heparin-calcium therapy: clinical and laboratory experience]Z Boda, K Rák
Orvosi Hetilap|October 19, 1980
[Von Willebrand's disease, with special reference to laboratory diagnosis (the ristomycin test)]Z Boda, K Rák
Orvosi Hetilap|February 20, 1983
[Essential athrombia: primary hereditary disorder of thrombocyte aggregation]Z Boda, K Rák
Orvosi Hetilap|January 29, 1978
[Ristomycin, a new throbocyte aggregating agent. Comparative study of ristocetin and ristomycin (preliminary report)]Z Boda, F Sztaricskai, K Rák
Orvosi Hetilap|May 20, 1990
[Individualized streptokinase treatment of acute myocardial infarct]M Udvardy, Z Boda, K Rák
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Orvosi Hetilap|April 4, 1993
[Heparin-Ca is not identical with low molecular weight heparin (LMWH)]Z Boda
Orvosi Hetilap|February 12, 1998
[Fibrinogen as an independent cardiovascular risk factor and the question of treatment with fibrinogen-lowering drugs]Z Boda
Lancet (London, England)|July 5, 1980
Haemostatic balance in congenital deficiency of platelet cyclo-oxygenaseK Rak, Z Boda
Orvosi Hetilap|June 17, 1984
[Laboratory control of patients treated with Syncumar]Z Boda, K Rák
Orvosi Hetilap|August 25, 1996
[Fibrinolysis and vascular diseases]M Udvardy, Z Boda
Orvosi Hetilap|October 29, 1989
[Subcutaneous heparin-calcium therapy: clinical and laboratory experience]Z Boda, K Rák
Orvosi Hetilap|October 19, 1980
[Von Willebrand's disease, with special reference to laboratory diagnosis (the ristomycin test)]Z Boda, K Rák
Orvosi Hetilap|February 20, 1983
[Essential athrombia: primary hereditary disorder of thrombocyte aggregation]Z Boda, K Rák
Orvosi Hetilap|January 29, 1978
[Ristomycin, a new throbocyte aggregating agent. Comparative study of ristocetin and ristomycin (preliminary report)]Z Boda, F Sztaricskai, K Rák
Orvosi Hetilap|May 20, 1990
[Individualized streptokinase treatment of acute myocardial infarct]M Udvardy, Z Boda, K Rák
Pageof 8